CORRECTION article

Front. Immunol., 28 April 2025

Sec. Vaccines and Molecular Therapeutics

Volume 16 - 2025 | https://doi.org/10.3389/fimmu.2025.1592118

Corrigendum: Adeno-associated virus as an effective malaria booster vaccine following adenovirus priming

This article is a correction to:

  1. Adeno-Associated Virus as an Effective Malaria Booster Vaccine Following Adenovirus Priming

    1. Read original article
Yenni Yusuf,Yenni Yusuf1,2Tatsuya YoshiiTatsuya Yoshii1Mitsuhiro IyoriMitsuhiro Iyori1Kunitaka YoshidaKunitaka Yoshida3Hiroaki MizukamiHiroaki Mizukami4Shinya FukumotoShinya Fukumoto5Daisuke S. YamamotoDaisuke S. Yamamoto6Asrar AlamAsrar Alam1Talha Bin EmranTalha Bin Emran1Fitri AmeliaFitri Amelia1Ashekul IslamAshekul Islam1Hiromu OtsukaHiromu Otsuka1Eizo TakashimaEizo Takashima7Takafumi TsuboiTakafumi Tsuboi7Shigeto Yoshida*Shigeto Yoshida1*
  • 1Laboratory of Vaccinology and Applied Immunology, Kanazawa University School of Pharmacy, Kanazawa University, Kanazawa, Japan
  • 2Department of Parasitology, Faculty of Medicine, University of Hasanuddin, Makassar, Indonesia
  • 3Kanazawa University Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan
  • 4Division of Gene therapy, Jichi Medical University, Shimotsuke, Japan
  • 5National Research Centre for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Obihiro, Japan
  • 6Division of Medical Zoology, Department of Infection and Immunity, Jichi Medical University, Shimotsuke, Japan
  • 7Division of Malaria Research, Proteo-Science Center, Ehime University, Matsuyama, Japan

A Corrigendum on
Adeno-associated virus as an effective malaria booster vaccine following adenovirus priming

By Yusuf Y, Yoshii T, Iyori M, Yoshida K, Mizukami H, Fukumoto S, Yamamoto DS, Alam A, Emran TB, Amelia F, Islam A, Otsuka H, Takashima E, Tsuboi T and Yoshida S (2019).Front. Immunol. 10:730. doi: 10.3389/fimmu.2019.00730

In the published article, there was an error in Figure 3 as published. In the Figure 3C, the image of the non-permeabilized AdHu5-PfCSP is a duplicate of the non-permeabilized AAV1-PfCSP-G(+) image. The corrected Figure 3 and its caption appear below.

Figure 3
www.frontiersin.org

Figure 3. Functional activity of AAV1-PfCSP-G(+). (A) Constructs of AAV1-PfCSP-G(+) and AdHu5-PfCSP-G(+). Expression of the pcsp gene cassette in AAV1 and AdHu5 was driven by a CMV promoter and CAG promoter, respectively. G, VSV-G. (B) Expression of PfCSP in HEK293T cells transduced with AdHu5-PfCSP (lane 1, MOI = 3), AAV1-PfCSP-G(–) (lane 2, MOI = 105), or AAV1-PfCSP-G(+) (lane 3, MOI = 105), as assessed by immunoblotting with mAb 2A10 at 48 h post-transduction. (C) Localization of PfCSP expression in HEK293T cells transduced with AAV1-PfCSP-G(+) (MOI = 105) and AdHu5-PfCSP (MOI = 10), as determined by IFA conducted as described in Figure 2C. (D) Anti-PfCSP IgG antibody responses. Groups of BALB/c mice (n = 10) were immunized with the indicated regimen at a 6-week interval. At 4 weeks post-boost, serum samples were collected from each mouse, and their anti-PfCSP IgG titers were determined by ELISA. AdHu5-PfCSP, AAV1-PfCSP-G(–), and AAV1-PfCSP (G+) are shown as AdHu5, AAV1-G(–), and AAV1-G(+), respectively. Bars and error bars indicate the means and SD of the values, respectively. Between-group differences were assessed with a Mann–Whitney U-test (*p < 0.05).

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: Plasmodium falciparum circumsporozoite protein, Pfs25, human adenovirus serotype 5, adeno-associated virus, malaria vaccine, transmission-blocking

Citation: Yusuf Y, Yoshii T, Iyori M, Yoshida K, Mizukami H, Fukumoto S, Yamamoto DS, Alam A, Emran TB, Amelia F, Islam A, Otsuka H, Takashima E, Tsuboi T and Yoshida S (2025) Corrigendum: Adeno-associated virus as an effective malaria booster vaccine following adenovirus priming. Front. Immunol. 16:1592118. doi: 10.3389/fimmu.2025.1592118

Received: 12 March 2025; Accepted: 01 April 2025;
Published: 28 April 2025.

Edited and Reviewed by:

Adrian John Frederick Luty, Institut de Recherche Pour le Développement (IRD), France

Copyright © 2025 Yusuf, Yoshii, Iyori, Yoshida, Mizukami, Fukumoto, Yamamoto, Alam, Emran, Amelia, Islam, Otsuka, Takashima, Tsuboi and Yoshida. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Shigeto Yoshida, c2hpZ2V0b0BwLmthbmF6YXdhLXUuYWMuanA=

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.